Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Open Forum Infectious Diseases · 30.10.2025 · 12 (11)
DOI: 10.1093/ofid/ofaf615 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.10.2025. Verfasst von Karam Mounzer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1. At 48 weeks, BIC + LEN (at either LEN dose) was highly effective at maintaining virologic suppression and was well tolerated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA.
- New York Medical College, Valhalla, New York, USA.
- Midway Immunology and Research Center, Fort Pierce, Florida, USA.
- Spectrum Health, Vancouver, British Columbia, Canada.
- Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia.
- School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.
ORCID-Profile: Karam Mounzer, Jihad Slim, Malcolm Hedgcock, Jorge Santana, Keith Aizen, Xu Zhang, Peter Sklar, Sorana Segal-Maurer
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Mounzer, K., Slim, J., Ramgopal, M., Hedgcock, M., Bloch, M., Santana, J., Aizen, K., Zhang, X., Sklar, P., Montezuma-Rusca, J. M., & Segal-Maurer, S. (2025). Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases, 12(11). https://doi.org/10.1093/ofid/ofaf615
Vancouver
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, et al. Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases. 2025;12(11). doi:10.1093/ofid/ofaf615
BibTeX
@article{Mounzer2025,
author = {Mounzer, Karam and Slim, Jihad and Ramgopal, Moti and Hedgcock, Malcolm and Bloch, Mark and Santana, Jorge and Aizen, Keith and Zhang, Xu and Sklar, Peter and Montezuma-Rusca, Jairo M and Segal-Maurer, Sorana},
title = {Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {11},
doi = {10.1093/ofid/ofaf615}
}
EUVIMED